Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Retinal progenitor cells for treatment of retinitis pigmentosa

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Retinitis pigmentosa (RP) is a severe form of blindness that runs in families with an incidence of 1:4000. A team at UC Irvine, is using cells called retinal progenitor cells…

Continue ReadingRetinal progenitor cells for treatment of retinitis pigmentosa

TY1 and Semaglutide to Treat Cardiometabolic HFpEF

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingTY1 and Semaglutide to Treat Cardiometabolic HFpEF

Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingNoncoding RNA drug TY2 for arrhythmogenic cardiomyopathy

Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingDevelopment of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders

Stem Cell-Based Cartilage Tissue Regeneration

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingStem Cell-Based Cartilage Tissue Regeneration

Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingAutologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence

Placental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Translational Candidate Placental-derived stem cells becoming a unique NK-like cell Area of Impact solid tissue cancers Mechanism of Action These expanded cells share many characteristics as NK cells but appear…

Continue ReadingPlacental Derived Natural Killer Cells to Target Solid Tumor Cancer Stem Cells (CSC)

Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice.

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Continue ReadingDevelopment of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice.

Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Duchenne muscular dystrophy (DMD) affects 1 in every 3,500 boys worldwide. DMD is caused by mutations in the gene encoding dystrophin, a protein key to muscle health. DMD patients are…

Continue ReadingCombination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy

Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells

  • Post author:
  • Post published:June 17, 2026
  • Post category:

Metastatic disease and the castration resistance remain tremendous challenges in the treatment of prostate cancer. New targeted treatments, such as the ant-testosterone medication enzalutamide, have improved the survival of men…

Continue ReadingClinical Development of an N-cadherin Antibody to Target Cancer Stem Cells
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us